Eli Lilly and Company (LLY) Lilly’s Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Breaking News
Eli Lilly and Company (LLY) Surges 5.1% — Developing Story
Eli Lilly and Company (LLY) Surges 5.1% — Developing Story
Eli Lilly and Company (LLY) Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) TD Cowen’s 46th Annual Health Care Conference
Eli Lilly and Company (NYSE: LLY) FY 2026 Corporate Conference
Eli Lilly and Company (LLY) Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Sec Form 10K
Eli Lilly and Company (NYSE: LLY) Sec Form 10K
Breaking News
Eli Lilly and Company (LLY) to acquire Orna Therapeutics
Eli Lilly and Company (NYSE: LLY) on Monday said it signed an agreement to acquire Orna Therapeutics, Inc., a biotechnology...